A Case of Extensive Alopecia Areata Following Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine with Favorable Outcome

    January 2023 in “ Journal of Cutaneous Immunology and Allergy ”
    Yoshihiro Matsuda, Yoshio Kawakami, Masaya Kawamoto, Yoji Hirai, Shin Morizane
    New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide →
    Studysummary This case report describes a 37-year-old woman who developed widespread hair loss following the BNT162b2 mRNA vaccine, which mostly recovered after topical corticosteroid treatment.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    A 37-year-old woman developed extensive alopecia areata (AA) following the first dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine. Initially presenting with a low-grade fever and coin-sized hair loss, her condition worsened to widespread hair loss. Laboratory tests showed increased serum C-reactive protein and decreased white blood cells. Despite the progression of hair loss, her condition improved significantly with topical corticosteroid therapy, resulting in substantial hair regrowth by day +310, leaving only one bald patch. This case, along with a review of 17 similar cases, suggests that COVID-19 vaccine-related AA may recover favorably with minimal treatment.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results